We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current BCRX market cap is 1.29B. The company's latest EPS is USD -1.0989 and P/E is -5.72.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 68.78M | 82.49M | 86.74M | 93.4M | 92.76M |
| Operating Income | -28.42M | -20.7M | -19.26M | -42.67M | -14.49M |
| Net Income | -53.33M | -75.33M | -36.15M | -61.73M | -35.38M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M |
| Operating Income | -99.46M | -174.76M | -177.72M | -148.44M | -103.71M |
| Net Income | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 509.74M | 529.89M | 522.92M | 516.96M | 467.89M |
| Total Liabilities | 838.02M | 918.6M | 933.91M | 972.49M | 944.06M |
| Total Equity | -328.29M | -388.71M | -410.99M | -455.53M | -476.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 175.28M | 334.72M | 588.15M | 550M | 516.96M |
| Total Liabilities | 137.03M | 353.98M | 695.14M | 844.6M | 972.49M |
| Total Equity | 38.25M | -19.26M | -106.99M | -294.6M | -455.53M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -47.51M | -66.33M | -86.22M | -95.14M | -53.68M |
| Investing | -107.11M | -126.14M | -103.03M | -131.5M | 28.76M |
| Financing | 5.08M | 34.43M | 35.66M | 32.49M | -1.05M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -89.58M | -137.22M | -142.16M | -161.85M | -95.14M |
| Investing | 77.93M | -6.86M | 15.8M | -128.24M | -131.5M |
| Financing | 99.1M | 302.7M | 359.67M | 88.03M | 32.49M |
| Market Cap | 1.29B |
| Price to Earnings Ratio | -5.72 |
| Price to Sales Ratio | 3.91 |
| Price to Cash Ratio | 11.72 |
| Price to Book Ratio | -2.85 |
| Dividend Yield | - |
| Shares Outstanding | 206.15M |
| Average Volume (1 week) | 3.36M |
| Average Volume (1 Month) | 3.91M |
| 52 Week Change | -26.61% |
| 52 Week High | 8.96 |
| 52 Week Low | 4.03 |
| Spread (Intraday) | 0.14 (2.19%) |
| Company Name | BioCryst Pharmaceuticals Inc |
| Address |
2711 centerville road wilmington, delaware 19808 |
| Website | https://www.biocryst.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
